Susceptibility of Urinary Tract Bacteria to Newer Antimicrobial Drugs

  • Manjula Mehta Dr. Harvansh Singh Judge Institute of Dental Science & Hospital, Panjab University, Chandigarh
  • Jyoti Sharma Dr. Harvansh Singh Judge Institute of Dental Science & Hospital, Panjab University, Chandigarh
  • Sonia Bhardwaj Dr. Harvansh Singh Judge Institute of Dental Science & Hospital, Panjab University, Chandigarh
Keywords: Antibiotic, Urinary tract infection, uropathogens

Abstract

Urinary tract infections (UTIs) are among the commonest types of bacterial infections. The antibiotic treatment for UTIs is associated with important medical and economic implications. Many different microorganisms can cause UTIs though the most common pathogens are E. coli and members of family Enterobacteriaceae. The knowledge of etiology and antibiotic resistance pattern of the organisms causing urinary tract infection is essential. The present study was undertaken to evaluate trends of antibiotic susceptibility of commonly isolated uropathogens using newer antimicrobial agents, prulifloxacin, fosfomycin (FOM) and doripenem. We conclude that maintaining a record of culture results and the antibiogram may help clinicians to determine the empirical and/or specific treatment based on the antibiogram of the isolate for better therapeutic outcome.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

Author Biographies

Manjula Mehta, Dr. Harvansh Singh Judge Institute of Dental Science & Hospital, Panjab University, Chandigarh
Associate Professor, Department of Microbiology
Jyoti Sharma, Dr. Harvansh Singh Judge Institute of Dental Science & Hospital, Panjab University, Chandigarh
Assistant Professor,Microbiology
Sonia Bhardwaj, Dr. Harvansh Singh Judge Institute of Dental Science & Hospital, Panjab University, Chandigarh
Assistant Professor,Microbiology

References

Foxman, B., K. L. Klemstine, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol. 2003; 13:144-150.

http://dx.doi.org/10.1016/S1047-2797(02)00272-7

Williams DH, Schaeffer AJ. Current concepts in urinary tract infections. Minerva Urol Nefrol. 2004; 56: 15-31.

PMid:15195028

Kunin CM. Urinary tract infections in females. Clin Infect Dis. 1994; 18:1-12.

http://dx.doi.org/10.1093/clinids/18.1.1

PMid:8054415

Patton JP, Nash DB, Abrutyn E. Urinary tract infections: Economic considerations. Medical clinics of North America. 1991;75:495-513.

PMid:1996046

Kaem SJ, Perry CM. Prulifloxacin. Drugs. 2004; 64:2221-2234.

http://dx.doi.org/10.2165/00003495-200464190-00005

Prats G, Roig C, Miro E, Navarro F, Mirelis B. In vitro activity of the active metabolites of Prulifloxacin (Af_3013) Compared with six other floroquinolones. Eur J lin Microbiol Infect Dis. 2002; 21:328-334.

http://dx.doi.org/10.1007/s10096-002-0709-1

PMid:12072950

Montanari MP, Mingoia M, Varaldo PE. In vitroantibacterial activities of AF 3013, the active metabolite of Prulifloxacin, against nosocomial and community Italian isolates. Antimicrob Agents Chemotherap. 2001; 45:3616-3622.

http://dx.doi.org/10.1128/AAC.45.12.3616-3622.2001

PMid:11709353 PMCid:PMC90882

Kahan FM, KAhan JS, Cassidy PJ, Knoop H. The mechanism of action of fosfomycin (Phosphomycin). Ann NY Acd Sci. 1974; 235:364-86.

http://dx.doi.org/10.1111/j.1749-6632.1974.tb43277.x

Hendin D, Stapley EO, Jackson M et al. Phosphomycin, a new antibiotic produced by strains of Streptomyces. Science (New York, NY).1969; 166: 122-3.

http://dx.doi.org/10.1126/science.166.3901.122

Warren JW, Abrutyn E, Hebel JR et al. Guidelines for antimicrobial treatment of uncomplicated actute bacterial cystitis and acute pylonephritis in women. Infectious Dis Society of America (IDSA). Clin Infect Dis. 1999; 29: 745-58.

http://dx.doi.org/10.1086/520427

PMid:10589881

Anonymous. Doripenem (Doribax)- A new parenteral carbapenem. The medical letter. 2008; 50:1278:5-7.

Cheesbrough M. District Laboratory Practice in Tropical Countries. Part 2 © Monica Cheesbrough.Examination of urine and antimicrobial sensitivity testing, 2000:pp. 105–143.

Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing: sixteenthinformational supplement. CLSI document M100-S16. Wayne, Pa: CLSI, 2006.

Carmignani G, Rose AFDe, Olivieri l, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin versus ciprofloxacin in the treatment of Adults with complicated urinary tract infections. Urologia International. 2005; 74:326-331.

http://dx.doi.org/10.1159/000084432

PMid:15897698

Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 2009;53(10):4508-10.

http://dx.doi.org/10.1128/AAC.00721-09

PMid:19687248 PMCid:PMC2764175

Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis. 2013;17(11):e966-70.

http://dx.doi.org/10.1016/j.ijid.2013.04.005

PMid:23742831

Gales AC, Azevedo HD, Cereda RF, Girardello R, Xavier DE. INVITA-A-DORI Brazilian Study Group. Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study. Braz J Infect Dis. 2011; 15(6):513-20.

http://dx.doi.org/10.1016/S1413-8670(11)70244-6

Published
2016-01-25
How to Cite
1.
Mehta M, Sharma J, Bhardwaj S. Susceptibility of Urinary Tract Bacteria to Newer Antimicrobial Drugs. Open Access Maced J Med Sci [Internet]. 2016Jan.25 [cited 2020Dec.5];4(1):22-4. Available from: https://www.id-press.eu/mjms/article/view/oamjms.2016.020
Section
A - Basic Science